AEON Biopharma, Inc.
AEON
$0.24
$0.000.60%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.50% | 7.15% | -10.52% | -27.73% | -36.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.82% | -14.50% | -41.40% | -49.94% | -59.16% |
| Operating Income | -10.82% | 14.50% | 41.40% | 49.94% | 59.16% |
| Income Before Tax | -3,238.81% | -135.54% | -193.37% | -100.02% | 99.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,238.81% | -135.54% | -193.37% | -100.02% | 99.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,238.81% | -135.54% | -193.37% | -100.02% | 99.46% |
| EBIT | -10.82% | 14.50% | 41.40% | 49.94% | 59.16% |
| EBITDA | -10.93% | 14.50% | 41.48% | 50.04% | 59.26% |
| EPS Basic | 38.17% | -101.39% | -102.31% | -64.04% | 98.40% |
| Normalized Basic EPS | 87.68% | 82.01% | 99.69% | 93.60% | 90.41% |
| EPS Diluted | 38.37% | -101.39% | -102.31% | -64.14% | 98.40% |
| Normalized Diluted EPS | 87.67% | 81.99% | 99.69% | 93.62% | 90.42% |
| Average Basic Shares Outstanding | 614.94% | 1,254.46% | 1,732.42% | 1,184.26% | 570.70% |
| Average Diluted Shares Outstanding | 614.90% | 1,254.22% | 1,731.57% | 1,184.31% | 570.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |